Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Standalone HPV Testing Recommended for Cervical Cancer Screening

By LabMedica International staff writers
Posted on 02 Oct 2018
The number of deaths from cervical cancer in the USA has decreased substantially since the implementation of widespread cervical cancer screening and has declined from 2.8 to 2.3 deaths per 100,000 women from 2000 to 2015.

The evidence on screening for cervical cancer has been reviewed with a focus on clinical trials and cohort studies that evaluated screening with high-risk human papillomavirus (hrHPV) testing alone or hrHPV and cytology together (co-testing) compared with cervical cytology alone.

The US Preventive Services Task Force (Rockville, MD, USA) besides reviewing and evaluating cervical cancer screening also commissioned a decision analysis model to evaluate the age at which to begin and end screening, the optimal interval for screening, the effectiveness of different screening strategies, and related benefits and harms of different screening strategies.

The experts reported on screening with cervical cytology alone, primary hrHPV testing alone, or co-testing can detect high-grade precancerous cervical lesions and cervical cancer. More...
Screening women aged 21 to 65 years substantially reduces cervical cancer incidence and mortality. The harms of screening for cervical cancer in women aged 30 to 65 years are moderate. Four studies identified in the review found that primary hrHPV testing detected higher rates of stage 3 (or worse) cervical intraepithelial neoplasia compared with the standalone Pap test in the first round of testing. In comparing the Pap, hrHPV and co-testing methods, the latter two methods were associated with higher colposcopy and false-positive rates.

The scientists concluded with high certainty that the benefits of screening every three years with cytology alone in women aged 21 to 29 years substantially outweigh the harms. They also concluded with high certainty that the benefits of screening every three years with cytology alone, every five years with hrHPV testing alone, or every five years with both tests (co-testing) in women aged 30 to 65 years outweigh the harms. Screening women older than 65 years who have had adequate prior screening and women younger than 21 years does not provide significant benefit. The anticipation is hrHPV testing every five years for women aged 30 to 65 could reduce cervical cancer mortality from 8.34 to 0.29 deaths per 1,000 women.

Lee A. Learman, MD, PhD, professor of obstetrics and gynecology, said, “HPV testing every five years is an attractive option for patients who want to avoid pelvic exams and Pap smears. The Pap test is well known and accepted by patients and women’s healthcare providers, and there would need to be powerful incentives to move away from it. Switching from Pap tests annually to every three years has been the USPSTF recommendation since 2012, but patient and provider preferences have been hard to change. I expect the same phenomenon will delay implementation of primary HPV screening every 5 years.” The study was published on August 21, 2018, in the Journal of the American Medical Association.

Related Links:
US Preventive Services Task Force


New
Gold Member
Collection and Transport System
PurSafe Plus®
Collection and Transport System
PurSafe Plus®
New
Laboratory Software
ArtelWare
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.